NCT05323149

Brief Summary

In this study, our aim is to investigate the role of tranexamic acid for modulating the inflammation in patients with traumatic brain injury (TBI).

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at below P25 for phase_3

Timeline
18mo left

Started May 2022

Longer than P75 for phase_3

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress73%
May 2022Oct 2027

First Submitted

Initial submission to the registry

March 27, 2022

Completed
16 days until next milestone

First Posted

Study publicly available on registry

April 12, 2022

Completed
1 month until next milestone

Study Start

First participant enrolled

May 18, 2022

Completed
5.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 10, 2027

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

October 15, 2027

Last Updated

January 2, 2026

Status Verified

December 1, 2025

Enrollment Period

5.3 years

First QC Date

March 27, 2022

Last Update Submit

December 27, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Percentage of patients with decreased the inflammatory response

    Percentage of patients with decreased the inflammatory response, as assessed by NLR measurements

    48 hours post-interventional (either placebo or TXA)

Study Arms (2)

Group C

PLACEBO COMPARATOR

Group C, will be received saline (loading dose of 1gm of saline 0.9%, followed by a 1gm of maintenance saline dose over 8 hours for 48 h).

Other: Saline

Group T

EXPERIMENTAL

Group T, will be received TXA (loading dose of 1gm of TXA, followed by a 1gm of maintenance dose over 8 hours for 48 h).

Drug: Tranexamic acid

Interventions

Giving TXA (loading dose of 1gm of TXA, followed by a 1gm of maintenance dose over 8 hours for 48 h).

Also known as: Cyclokapron
Group T
SalineOTHER

Giving saline (loading dose of 1gm of saline 0.9%, followed by a 1gm of maintenance saline dose over 8 hours for 48 h).

Also known as: Normal saline
Group C

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Isolated traumatic brain injury patients (mild or moderate cases)
  • GCS \> 8
  • non penetrating TBI in 8 hours onset
  • Age ≥ 18 years

You may not qualify if:

  • Patient in cardiac arrest
  • Patients with coagulopathies
  • Renal failure patients
  • pregnancy
  • Patient refusal to participate

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assiut university hospital

Asyut, Assuit, Assuit universi, Egypt

RECRUITING

MeSH Terms

Interventions

Sodium ChlorideSaline SolutionTranexamic Acid

Intervention Hierarchy (Ancestors)

ChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium CompoundsCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical PreparationsCyclohexanecarboxylic AcidsAcids, CarbocyclicCarboxylic AcidsOrganic Chemicals

Central Study Contacts

Omar Soliman

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer of anesthesia and ICU

Study Record Dates

First Submitted

March 27, 2022

First Posted

April 12, 2022

Study Start

May 18, 2022

Primary Completion (Estimated)

September 10, 2027

Study Completion (Estimated)

October 15, 2027

Last Updated

January 2, 2026

Record last verified: 2025-12

Locations